Tag Archives: biosimilar

Specialty Pharmacy News Roundup: October 2023

The following company announcements are just a few of the specialty pharmacy company activities from this month. Subscribe to AMI’s Specialty Pharmacy Database to stay up to date on company and industry trends

Celltrion Healthcare Contracts with CarePartners Pharmacy for Yuflyma

Celltrion Healthcare recently signed an agreement with Libertyville, IL-based CarePartners Pharmacy to sell its Humira biosimilar Yuflyma in the U.S. market

Specialty Pharmacy News Roundup: September 2023

Subscribe to AMI’s Specialty Pharmacy Database to stay up to date on specialty pharmacy company and industry trends

Optum Specialty Fusion™ Launched To Streamline Care and Lower Costs

Optum Specialty Fusion™ was launched to streamline treatment decision-making for care providers, helping patients get on their therapies faster

ACA Supreme Court Deliberations and Any Impact on Biosimilars?

If the court strikes down the ACA entirely, biosimilars on the U.S. market or in the FDA approval pipeline would have to either be grandfathered in or face a regulatory wind-down

Oncology Biosimilars: Opportunity or Not?

Oncology Biosimilars: Opportunity or Not? VBCC – April 2016, Vol 7, No 3 – Employers’ Perspective F. Randy Vogenberg, PhD, RPh, Partner Access Market Intelligence Martha M. Rumore, PharmD, JD, MS, LLM, FAPhA The United States has the largest biologic drugs market and high prices for biologics, such as monoclonal antibodies, therapeutic proteins, immunomodulators, and […]

Biosimilar Confusion and Insights

Since Virginia became the first state in May 2013 to enact legislation regulating a pharmacist’s substitution of an interchangeable biologic drug for a prescribed reference biologic drug, there has not been much activity or clarity on the issue. This issue continues to pit manufacturer versus manufacturer, and other stakeholders against each other in the policy […]